Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0017638 (
glioma
)
30,880
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Semaphorins comprise a family of molecules implicated in the guiding of growing axons and neuronal progenitor cells. Further, semaphorins have been suggested to play a role in cancer metastasis. Neuropilins 1 and 2 are cell surface receptors for soluble class 3 semaphorins. Plexins are direct receptors for membrane-bound semaphorins and, by binding to neuropilins, coreceptors necessary for class 3 semaphorin signaling. We here report that human malignant
glioma
cell lines express neuropilins 1 and 2 mRNA and protein, as well as either
plexin A1
, A2, or B1. Further, all
glioma
cell lines express SEMA3A and SEMA3C and exhibit SEMA3A binding sites. Exogenous SEMA3A expressed in 293 or U87MG cells has no collapsing or chemorepulsive activities on
glioma
cells as determined by F-actin staining and collagen coculture assays. In summary, human
glioma
cells express class 3 semaphorins and receptors for soluble and membrane-bound semaphorins, suggesting a possible role of the semaphorin/neuropilin system in the interactions of human malignant
glioma
with the host's central nervous and immune systems.
...
PMID:Human malignant glioma cells express semaphorins and their receptors, neuropilins and plexins. 1273 Sep 58
Neuropilin-1 (NRP1) functions as a coreceptor through interaction with
plexin A1
or vascular endothelial growth factor (VEGF) receptor during neuronal development and angiogenesis. NRP1 potentiates the signaling pathways stimulated by semaphorin 3A and VEGF-A in neuronal and endothelial cells, respectively. In this study, we investigate the role of tumor cell-expressed NRP1 in
glioma
progression. Analyses of human
glioma
specimens (WHO grade I-IV tumors) revealed a significant correlation of NRP1 expression with
glioma
progression. In tumor xenografts, overexpression of NRP1 by U87MG gliomas strongly promoted tumor growth and angiogenesis. Overexpression of NRP1 by U87MG cells stimulated cell survival through the enhancement of autocrine hepatocyte growth factor/scatter factor (HGF/SF)/c-Met signaling. NRP1 not only potentiated the activity of endogenous HGF/SF on
glioma
cell survival but also enhanced HGF/SF-promoted cell proliferation. Inhibition of HGF/SF, c-Met and NRP1 abrogated NRP1-potentiated autocrine HGF/SF stimulation. Furthermore, increased phosphorylation of c-Met correlated with
glioma
progression in human
glioma
biopsies in which NRP1 is upregulated and in U87MG NRP1-overexpressing tumors. Together, these data suggest that tumor cell-expressed NRP1 promotes
glioma
progression through potentiating the activity of the HGF/SF autocrine c-Met signaling pathway, in addition to enhancing angiogenesis, suggesting a novel mechanism of NRP1 in promoting human
glioma
progression.
...
PMID:Neuropilin-1 promotes human glioma progression through potentiating the activity of the HGF/SF autocrine pathway. 1736 61
Class three semaphorins (SEMAs) were originally shown to be mediators of axon guidance that repelled axons and collapsed growth cones, but it is now evident that SEMA3F, for example, has similar effects on tumor cells and endothelial cells (EC). In both human U87MG
glioma
cells and human umbilical vein EC, SEMA3F induced rapid cytoskeletal collapse, suppressed cell contractility, decreased phosphorylation of cofilin, and inhibited cell migration in culture. Analysis of the signaling pathways showed that SEMA3F formed a complex with NRP2 (neuropilin-2) and
plexin A1
. These interactions eventually led to inactivation of the small GTPase, RhoA, which is necessary for stress fiber formation and cytoskeleton integrity. A novel upstream RhoA mediator was shown to be ABL2, also known as ARG, a membrane-anchored nonreceptor tyrosine kinase. Within minutes after the addition of SEMA3F, ABL2 directly bound
plexin A1
but not to a
plexin A1
mutant lacking the cytoplasmic domain. In addition, ABL2 phosphorylated and thereby activated p190RhoGAP, which inactivated RhoA (GTP to GDP), resulting in cytoskeleton collapse and inhibition of cell migration. On the other hand, cells overexpressing an ABL2 inactive kinase mutant or treated with ABL2 small interfering RNA did not inactivate RhoA. Cells treated with p190RhoGAP small interfering RNA also did not inactivate RhoA. Together, these results suggested that ABL2/ARG is a novel mediator of SEMA3F-induced RhoA inactivation and collapsing activity.
...
PMID:ABL2/ARG tyrosine kinase mediates SEMA3F-induced RhoA inactivation and cytoskeleton collapse in human glioma cells. 1866 May 2